The Effect of Aprotinin on Thrombelastography in Vitro [PDF]
Anaesthesia and Intensive Care, 1996 The effect of low dose (50 KIU/ml) and high dose (200 KIU/ml) aprotinin on standard thrombelastographic variables (r, K, α, MA) was examined in vitro using blood from forty ASA Class I patients. Both concentrations of aprotinin resulted in minor increases in r time above the normal range (P<0.05).
Neville M. Gibbs, George A. Chalkiadis
openaire +3 more sources
Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot [PDF]
, 2017 Objective: Kaolin-based activated clotting time assessed by HEMOCHRON (HkACT) is a clinical standard for heparin monitoring alone and combined with aprotinin during cardiopulmonary bypass (CPB).
Furrer, Lukas +7 more
core
Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery [PDF]
, 2002 Objective: Effects of aprotinin in off-pump coronary artery bypass (OPCAB) surgery have not yet been described. This study analyses hemostasiologic changes and potential benefit in OPCAB patients treated with aprotinin.
Berdat, P.A. +5 more
core +1 more source
Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery [PDF]
, 2017 Objective: Effects of aprotinin in off-pump coronary artery bypass (OPCAB) surgery have not yet been described. This study analyses hemostasiologic changes and potential benefit in OPCAB patients treated with aprotinin.
Berdat, P.A. +5 more
core
Mediators of leukocyte yctivation play a role in disseminated intravascular coagulation during orthotopic liver transplantation [PDF]
, 1994 Leukocytes play an important role in the development of disseminated intravascular coagulation (DIC). In the reperfusion phase of OLT a DIC-like situation has been described and has been held responsible for the high blood loss during this phase.
Bechstein, W. O. +6 more
core
Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1 [PDF]
, 2020 Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., ε-aminocaproic acid and tranexamic acid); however, they ...
Arbing, Mark A +8 more
core +2 more sources
Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease [PDF]
, 1992 Autoimmune chronic active liver disease (ACALD), a major indication for liver transplantation, is associated strongly with antigenic determinants HLA-B8 and DR3.
Block, GD +6 more
core +1 more source
Aprotinin Inhibits SARS-CoV-2 Replication [PDF]
, 2020 Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current coronavirus disease 19 (COVID-19) pandemic. Protease inhibitors are under consideration as virus entry inhibitors that prevent the cleavage of the coronavirus spike (S ...
Bechtel, Marco +13 more
core +1 more source
Risk factors for deterioration of renal function after coronary artery bypass grafting [PDF]
, 2010 Objective: Various definitions of impairment of renal function after coronary artery bypass grafting (CABG) are used in the literature. Depending on the definition, several risk factors are identified.
de Wolf, Andre +5 more
core +2 more sources
Impact of aprotinin and renal function on mortality: a retrospective single center analysis [PDF]
, 2011 Background An estimated up to 7% of high-risk cardiac surgery patients return to the operating room for bleeding. Aprotinin was used extensively as an antifibrinolytic agent in cardiac surgery patients for over 15 years and it showed efficacy in reducing
A Laupacis +34 more
core +3 more sources